BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BridgeBio Pharma (BBIO), Healthequity (HQY) and Alny...

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Healthequity (HQY) and Alnylam Pharma (ALNY)

Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Pharma today and set a price target of $111.00. According to TipRanks, Amin i...

BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler

RBC Capital analyst Luca Issi maintained a Buy rating on BridgeBio Pharma on July 7 and set a price target of $100.00. The company’s shares closed ...

RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and Bridge...

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

BridgeBio Pharma ( ($BBIO) ) has provided an update. On July 1, 2026, BridgeBio Pharma entered into an investment agreement with funds managed by S...

BridgeBio Raises $934 Million via Preferred Equity Financing

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), BridgeBio Pharma (BBIO) and Jazz Pharm...

Analysts’ Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)

BridgeBio Pharma ( ($BBIO) ) has issued an announcement. On June 22, 2026, BridgeBio Pharma held its annual meeting of stockholders, at which direc...

BridgeBio shareholders approve board changes and equity plan

Healthcare stocks are in focus this month as investors look for steady growth and clear catalysts in a market dealing with volatility and uneven se...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BBIO	$81.38	+1.34%	1.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BBIO	$81.38	+1.3%	1.44M
3
4
5
6

BBIO

BBIO

Get BridgeBio Pharma Inc. Data in Excel

Get BridgeBio Pharma Inc. Data in Excel